Effect of Qianggan capsules on insulin resistance index and liver fibrosis score in patients with nonalcoholic fatty liver disease

Ou Qiang; Xu YanHua; Qu LiJuan; Huang Ling

doi:10.3969/j.issn.1001-5256.2016.10.027

Issue 10

Oct. 2016

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2016 > 32(10): 1951-1954

PDF( 1532 KB)

Effect of Qianggan capsules on insulin resistance index and liver fibrosis score in patients with nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2016.10.027

Department of Infectious Diseases, The Eighth People′s Hospital of Shanghai

Published Date: 2016-10-20

Abstract

Abstract

Objective To investigate the effect of Qianggan capsules on liver fibrosis score and insulin resistance index in patients with nonalcoholic fatty liver disease( NAFLD). Methods A total of 85 NAFLD patients who were treated in the Eighth People's Hospital of Shanghai from August 2014 to July 2015 were enrolled and randomly divided into treatment group( 45 patients) and control group( 40 patients).The patients in the treatment group were given Qianggan capsules,and those in the control group were given polyene phosphatidylcholine capsules. The course of treatment was 24 weeks for both groups. The changes in serum aminotransferases [aspartate aminotransferase( AST)and alanine aminotransferase( ALT) ],homeostasis model assessment of insulin resistance( HOMA-IR),and NAFLD fibrosis score( NAFLDFS) after treatment were observed in both groups. The t-test was used for comparison of continuous data between groups,before-after comparison within each group was made by paired t-test; and the chi-square test was used for comparison of categorical data between groups. Results Both groups showed significant improvements in ALT and AST levels after treatment( all P < 0. 01). After treatment the treatment group showed significant reductions in HOMA-IR and NAFLDFS( 3. 58 ± 0. 85 vs 2. 48 ± 0. 78,t = 6. 40,P < 0. 01;-1. 78 ±1. 24 vs-2. 35 ± 0. 98,t = 2. 40,P < 0. 01) and the treatment group had significantly lower HOMA-IR and NAFLDFS than the control group( 12. 48 ± 0. 78 vs 3. 09 ± 0. 89,t = 3. 36,P < 0. 01;-2. 35 ± 0. 98 vs-1. 48 ± 1. 08,t = 3. 80,P < 0. 01). No serious adverse events were observed during the course of treatment. Conclusion Qianggan capsules not only reduce the levels of serum aminotransferases,but also improve insulin resistance and reduce fibrosis degree in NAFLD patients.
- fatty liver,
- Qianggan capusule,
- insulin resistance,
- nonalcoholic fatty liver disease fibrosis score

FullText(HTML)

References(18)

References

[1]RAU M,WEISS J,GEIER A.Non-alcoholic fatty liver disease(NAFLD)[J].Dtsch Med Wochenschr,2015,140(14):1051-1055.

[2]JI XL,GE YD,AN MM,et al.Correlation analysis between nonalcoholic fatty liver disease and metabolic syndrome[J].Chin J Clin Pharmacol Ther,2014,19(6):666-670.(in Chinese)季学磊,葛艺东,安民民,等.非酒精性脂肪肝与代谢综合征的临床相关性分析[J].中国临床药理学与治疗学,2014,19(6):666-670.

[3]YAN J,XIE W,OU WN,et al.Epidemiological survey and risk factor analysis of fatty liver disease of adult residents,Beijing,China[J].J Gastroenterol Hepatol,2013,28(10):1654-1659.

[4]ANGULO P.Long-term mortality in nonalcoholic fatty liver disease:is liver histology of any prognostic significance?[J].Hepatology,2010,51(5):373-375.

[5] Fatty Liver and Alcoholic Liver Disease Study Group of the Chinese Liver Disease Association.Guidelines for diagnosis and treatment of nonalcoholic fatty liver diseases(revised in January 2010)[J].Chin J Intern Med,2010,49(3):275-278.(in Chinese)中华医学会肝病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南(2010年1月修订)[J].中华内科杂志,2010,49(3):275-278.

[6]FRIEDMAN SL.Liver fibrosis in 2012:Convergent pathways that cause hepatic fibrosis in NASH[J].Nat Rev Gastroenterol Hepatol,2013,10(2):71-72.

[7]VERNON G,BARANOVA A,YOUNOSSI ZM.Systematic review:the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults[J].Aliment Pharmacol Ther,2011,34(3):274-285.

[8]SANAL MG.Biomarkers in nonalcoholic fatty liver disease:theemperor has no clothes?[J].World J Gastroenterol,2015,21(11):3223-3231.

[9]SHEN F,ZHENG RD,MI YQ,et al.Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients[J].World J Gastroenterol,2014,20(16):4702-4711.

[10]LEE SS,PARK SH.Radiologic evaluation of nonalcoholic fatty liver disease[J].World J Gastroenterol,2014,20(23):7392-7402.

[11]ANGULO P,HUI JM,MARCHESINI G,et al.The NAFLD fibrosis score:a noninvasive tsystem that identifies liver fibrosis in patients with NAFLD[J].Hepatology,2007,45(4):846-854.

[12]WANG Y,LIANG J,LI HY,et al.Relationship of nonalcoholic fatty liver disease fibrosis score with metabolic syndrome and its components[J].Chin J endocrirol metab,2013,29(5):406-409.(in Chinese)王玉,梁军,李洪艳,等.非酒精性脂肪肝纤维化评分与代谢综合征及其各组分的相关性研究[J].中华内分泌代谢杂志,2013,29(5):406-409.

[13]MUSSO G,GAMBINO R,CASSADER M,et al.Meta-analysis:natural history of non-alcoholic fatty liver disease(NAFLD)and diagnostic accuracy of non-invasive tests for liver disease severity[J].Ann Med,2011,43(8):617-649.

[14]ROMBOMS K,MARRA F.Molecular mechanisms of hepatic fibrosis in Non-alcoholic steatohepatitis[J].Dig Dis,2010,28(1):229-235.

[15]WEI YC,ZHU R,XIA LL,et al.Evaluation of different indices of insulin resistance in overweight and obese population[J].Shandong Med J,2015,55(46):14-16.(in Chinese)尉耘翠,祝茸,夏丽莉,等.超重及肥胖人群中不同胰岛素抵抗计算指数准确性评价[J].山东医药,2015,55(46):14-16.

[16]LIU ZY,LYU JX.Efficacy of Qianggan capsules in treatment of nonalcoholic fatty liver disease[J].Mod J Integr Tradit Chin West Med,2014,23(6):600-601.(in Chinese)刘子永,吕俊旭.强肝胶囊治疗非酒精性脂肪肝疗效观察[J].现代中西医结合杂志,2014,23(6):600-601.

[17]GU S,HUANG MX.Clinical observation of Qianggan capsule in the treatment of non alcoholic of non-alcoholic fatty liver fibrosis[J].Chin J Hepatol,2011,19(10):791-792.(in Chinese)古赛,黄秒兴.强肝胶囊治疗非酒精性脂肪性肝纤维化的疗效[J].中华肝脏病杂志,2011,19(10):791-792.

[18]HAO LH.Effects of Qianggan capsules on clinical symptoms and liver function in patients with nonalcoholic fatty liver disease[J].J Clin Med Pract,2015,19(1):126-127.(in Chinese)郝丽红.强肝胶囊对非酒精性脂肪肝患者临床症状改善情况及肝功能的影响[J].实用临床医药杂志,2015,19(1):126-127.

Relative Articles

[1]	Tingting DU, Hui YAO, Xiaohong CHEN, Jie LUO, Luhong YANG, Lifang FENG, Xiaoqian CHEN, Man HU, Juan LUO. Clinical features of hypopituitarism with nonalcoholic fatty liver disease after sellar tumor surgery in children[J]. Journal of Clinical Hepatology, 2023, 39(6): 1332-1339. doi: 10.3969/j.issn.1001-5256.2023.06.013
[2]	Rong JIANG, Yongxia LI. Value of triglyceride-glucose index combined with obesity index in predicting nonalcoholic fatty liver disease in individuals with obstructive sleep apnea[J]. Journal of Clinical Hepatology, 2023, 39(3): 546-551. doi: 10.3969/j.issn.1001-5256.2023.03.010
[3]	Huawei QIU, Tianfu LIANG, Zhi ZHONG, Xuejiao JIA, Yang JIANG. Trend and prediction of the disease burden of acute hepatitis B in China[J]. Journal of Clinical Hepatology, 2023, 39(11): 2575-2579. doi: 10.3969/j.issn.1001-5256.2023.11.010
[4]	Zhiqiang ZHANG, Wei CHEN, Bo LIU. Value of spleen volume in predicting portal hypertensive gastropathy and its severity in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2023, 39(4): 826-833. doi: 10.3969/j.issn.1001-5256.2023.04.013
[5]	Xing DAI, Ben GAO, Xinxin ZHANG, Yanyan SUN, Wentao JIANG, Jiang LI. Establishment and validation of a risk prediction model for early-stage complications after liver transplantation[J]. Journal of Clinical Hepatology, 2022, 38(2): 402-408. doi: 10.3969/j.issn.1001-5256.2022.02.027
[6]	Dongxu WANG, Nan NAN, Hao BING, Lianjie LIN. Value of triglyceride-glucose index and body mass index in predicting nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus[J]. Journal of Clinical Hepatology, 2022, 38(5): 1064-1068. doi: 10.3969/j.issn.1001-5256.2022.05.017
[7]	Bingqi MA, Huijuan MENG, Wei ZHANG, Xiaofeng DONG, Meng WANG, Jie DOU, Yuning WU, Shiping LI. Prognostic value of several immune and inflammatory indices after curative-intent resection for intrahepatic cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2022, 38(9): 2061-2066. doi: 10.3969/j.issn.1001-5256.2022.09.021
[8]	Yiping LIU, Xinping LI, Lei CHEN, Jinju XIA, Kairong SONG, Ningyang JIA, Wanmin LIU. Accurate imaging diagnosis and recurrence prediction of hepatocellular carcinoma based on artificial intelligence[J]. Journal of Clinical Hepatology, 2022, 38(3): 521-527. doi: 10.3969/j.issn.1001-5256.2022.03.006
[9]	Guoxu FANG, Qinghua ZHANG, Yongying HUANG, Jianmin WANG, Jingfeng LIU. Application of bioinformatics in predicting the risk of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(1): 15-19. doi: 10.3969/j.issn.1001-5256.2022.01.002
[10]	Shaojie DUAN, Zunjing LIU, Jialiang CHEN, Shukun YAO. Value of lipid accumulation product and visceral fat index in predicting nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2022, 38(1): 129-134. doi: 10.3969/j.issn.1001-5256.2022.01.020
[11]	Wang ZheXuan, Wang EnXin, Xia DongDong, Bai Wei, Wang QiuHe, Yuan Jie, Li XiaoMei, Niu Jing, Guo WenGang, Li Kai, Yin ZhanXin, Han GuoHong. Value of Child-Pugh score versus albumin-bilirubin grade in predicting the prognosis of unresectable hepatocellular carcinoma treated by transarterial chemoembolization[J]. Journal of Clinical Hepatology, 2020, 36(1): 113-117. doi: 10.3969/j.issn.1001-5256.2020.01.025
[12]	Feng Gong, Zhang Yan, Yan QinQin, Liu Jing, Liu ManLing, Fan LiPing, Lin SiCen, He Na, Mi Man. Construction and analysis of a predictive model for progressive liver fibrosis in nonalcoholic fatty liver disease based on LASSO regression[J]. Journal of Clinical Hepatology, 2020, 36(10): 2214-2218. doi: 10.3969/j.issn.1001-5256.2020.10.011
[13]	Chen QinQin, Liang CanCan, Yang LiJun, Meng Qing, Ding YongNian. A clinical analysis of Uygur patients with acute ischemic cerebral infarction complicated by nonalcoholic fatty liver disease in Urumqi, China[J]. Journal of Clinical Hepatology, 2018, 34(6): 1259-1263. doi: 10.3969/j.issn.1001-5256.2018.06.025
[14]	Zhang LiHang, Wang ShanJuan, Lu LunGen, Liu YanLi, Wang YiFei, Xie JinBi. Predictive value of coagulation test parameters for acute upper gastrointestinal bleeding in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2018, 34(10): 2130-2135. doi: 10.3969/j.issn.1001-5256.2018.10.014
[15]	Feng Gong, Han HaiJing, Qi Xue, Mi Man, Tian QiuMei, Niu ChunYan. Establishment of a noninvasive diagnosis equation for nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2018, 34(6): 1264-1267. doi: 10.3969/j.issn.1001-5256.2018.06.026
[16]	Zhang HaiYue, Zhou Pei, Gong ZuoJiong. Predictive value of HBs Ag quantification in pegylated interferon therapy for chronic hepatitis B[J]. Journal of Clinical Hepatology, 2016, 32(5): 977-980. doi: 10.3969/j.issn.1001-5256.2016.05.041
[17]	Wang WenJun, Zhao Yan, Xia DongDong, Wang EnXin, Liu Lei, Han GuoHong. Predictive value of neutrophil-lymphocyte ratio and its dynamic change in patients with hepatocellular carcinoma undergoing transarterial chemoembolization[J]. Journal of Clinical Hepatology, 2016, 32(6): 1139-1144. doi: 10.3969/j.issn.1001-5256.2016.06.024
[18]	Huang ShuiWen, Liu BaoRong, Chen MingSheng, Lin Chun, Zhou Rui, Yang HuiAn, Jiang XiaoYan, Pan Chen, Li DongLiang. Establishment of a predictive model for early virologic response in previously untreated chronic hepatitis B patients treated with telbivudine[J]. Journal of Clinical Hepatology, 2016, 32(7): 1287-1291. doi: 10.3969/j.issn.1001-5256.2016.07.014
[19]	Zhang ZhiQiao, Wang GongSui, Kang KaiFu, Wu GuoBiao, Wang Peng. Analysis of high-risk groups and predictive factors for hepatic steatosis in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2015, 31(7): 1123-1125. doi: 10.3969/j.issn.1001-5256.2015.07.030
[20]	Xie YanDi, Feng Bo, Gao Yan, Wei Lai. Predictive factors for mortality in patients with alcoholic cirrhosis[J]. Journal of Clinical Hepatology, 2013, 29(11): 852-857. doi: 10.3969/j.issn.1001-5256.2013.10.013

Supplements(0)

Cited By

Cited by

Periodical cited type(4)

1.	郭新华，王佳慧，段雪琳，彭岳，赵铁建，郑洋，赵斌. 金属离子代谢：慢性肝病中医药防治新思路. 临床肝胆病杂志. 2024(07): 1498-1504 . 本站查看
2.	董昌君，张先林. 铜死亡在肝细胞癌发病机制中的研究进展. 中国普通外科杂志. 2024(07): 1172-1179 .
3.	刘诗卉，李冬冬，张宏坤，刘传苗，吴执竞，赵文. 细胞死亡在NAFLD发生发展中的研究进展. 齐齐哈尔医学院学报. 2024(16): 1578-1582 .
4.	朱明强，谢星，廖启成，何晓，丁佑铭，王小华. 铜死亡的发生机制及在肝脏疾病中的作用. 临床肝胆病杂志. 2024(11): 2332-2337 . 本站查看

Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2572) PDF downloads(436)

Effect of Qianggan capsules on insulin resistance index and liver fibrosis score in patients with nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2016.10.027